JAX Research on Microbiome Changes in Short- and Long-Term ME/CFS is now Available Online

Ruoyun Xiong (top left), Courtney Gunter (bottom left), Julia Oh Lab (middle), Derya Unutmaz (top right), Lucinda Bateman and Suzanne D Vernon (bottom right).

We are very excited to announce that in collaboration with the lab of Julia Oh at The Jackson Laboratory, which studies the microbiome in ME/CFS for the JAX CRC, we have just posted the full preprint of our new ME/CFS microbiome paper on BioRxiv, which will continue to be updated following reviewer comment and peer-review. In this detailed study led by Ruoyun Xiong, we did deep multi-omics, where we performed shotgun metagenomics of the gut microbiota and plasma metabolomics in 79 healthy controls and two cohorts of ME/CFS patients: 75 with short-term disease (<4 years), and 79 patients with long-term disease (>10 years). We also correlated these data to clinical information collected from subject questionnaires, and built multiple state-of-the-art classifiers that were able to differentiate short or long-term ME/CFS from each other, or ME/CFS from healthy controls.

The gut microbiome has been recently studied as a potential contributor to ME/CFS, and previous groups have shown that ME/CFS patients have frequent gastrointestinal (GI) disturbances, and changes in their gut microbiota compared to healthy controls. A few of the major differences that we found are that ME/CFS subjects had reduced gut microbiome diversity (fewer members) and richness. High diversity is associated with ecosystem health, and less diverse ecosystems are associated with decreased resilience and a susceptibility to colonization by pathogenic microbes. We also noticed a change in the ratio of the overall amounts of Firmicutes to Bacteroidetes phyla. Changes in this ratio have previously been noted in some chronic disorders and inflammatory diseases, such as inflammatory bowel disease (IBD). When looking at short-term vs. long-term ME/CFS, we found that subjects with a disease duration of <4 years had more microbial dysbiosis, but ME/CFS subjects with a disease duration of <10 years had more severe phenotypic and metabolic abnormalities.

One of the major problems that ME/CFS patients face is that there is no standard diagnostic test for ME/CFS. Our use of multiple ‘omics data greatly increased classification accuracy between ME/CFS subjects and healthy controls, and identified microbial and metabolic features that could be interesting to investigate further to find therapeutic strategies.

To read the full preprint on BioRxiv, click here.

One thought on “JAX Research on Microbiome Changes in Short- and Long-Term ME/CFS is now Available Online

  1. Dear JAX ME/CFS Center,

    for you being engaged to mainstream ME/CFS into modern science and medicine to find the true nature/origin of ME/CFS&FM and to treat it, the following information regarding Markov clinic’s revolutionary findings on CFS/ME, would be interesting, namely:

    till the moment being ME/CFS remained unexplained for the world medicine,
    and patients worldwide are still suffering from ME/CFS.
    Markov Clinic, Kyiv, Ukraine (https://vitacell.com.ua) and Dr.-med.Igor Markov, declares with full responsibility that the true nature/origin of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (ME/CFS) has been discovered! and as a result of 12-year (2009-2021) systematic clinical studies (more than 4500 patients with CFS/ME, adults&children) it’s found a revolutionary unique diagnostic-therapeutical solution to its problem:
    under the mask of mysterious pandemic ME/CFS in more than in 95% cases of ME/CFS
    hides a new previously unknown disease/diagnosis Chronic Bacterial Intoxication Syndrome© (CBIS).
    It’s outlined in the study “Chronic Bacterial Intoxication Syndrome under the mask of CFS/ME”
    (the whole study consists of Reports 1-9; Reports 1-6 “CBIS… Clinical Diagnosis” have been published in proceedings of the 8th Intern.Congress on Infectious Diseases (Febr.15-16, 2021, London, UK): https://www.longdom.org/proceedings/chronic-bacterial-intoxication-syndrome-under-the-mask-of-cfsme-59051.html , pdf./HTML, p.32-116).

    The findings confirm that CBIS is the clinical manifestation of a focus of chronic bacterial infection in the kidneys.
    This clinically locally asymptomatic latent focus of chronic bacterial infection in the kidneys (Nephrodysbacteriosis© is mainly due to a post-antibiotic disorder of local immunity of the kidneys mucous membranes in more than 90% of children&adults with ME/CFS-CBIS after over-use of antibiotics (often – beginning from childhood, especially by repeated and long courses).
    It occurs when the mucous membranes of the kidneys by upward path are autoinfected by bacteria (extracted in warm urine) from patient’s own intestines or/& from nasopharynx. As a result of the vital activity of bacteria, endo- and exotoxins are released & persisted in the kidneys for years.
    It leads to development of endotoxicosis & severe general intoxication of organism with toxic damage to various organs and systems and to the subsequent development of ME/CFS-CBIS with more than 70 clinical symptoms its manifestation.
    Available is full clinical diagnostics ME/CFS-CBIS and cure with mono-/bi-/poly-valent autovaccines (which may be used unlimited individually “from a patient – to this patient”)
    without traditional prescribing of antibiotics with full convalescence/recovery, proven on 4288 patients with efficacy upto 92.7% depending on disease duration & previous cure.

    When researching ME/CFS, there were detected and established 2 new diseases/diagnosis:
    1.Nephrodysbacteriosis©
    2. Chronic Bacterial Intoxication Syndrome© (CBIS) with more than 70 clinical symptoms and syndromes of its manifestation, which hides under ME/CFS.

    In connection with the COVID-19 pandemic, it should be forecasted and expected a sharp explosive increase of cases of exacerbation or primary diagnosing of ME/CFS-CBIS which will mistakenly pass under the mask of post-infectious or post-Covid asthenia (weakness) and of so called Long-Covid. This should be expected mainly after severe forms of coronavirus infection
    in patients, who were prescribed massive and long-term courses of antibiotics use, with the subsequent development or exacerbation of their post-antibiotic Nephrodysbacteriosis and CBIS.
    We assess that LONG-COVID with ME/CFS-symptoms in most cases is due to Nephrodysbacteriosis that causes ME/CFS-CBIS.

    The discovery refers to health care and focuses on the importance of research into bacteria and their toxins in the kidneys which cause ME/CFS, to be right diagnosed as Chronic Bacterial Intoxication Syndrome© (CBIS).

    CDC has published comments of Markov Clinic on Systematic Review Report for Diagnosis and Treatment of ME/CFS for 2021 https://www.regulations.gov/comment/CDC-2021-0053-0010

    Markov Clinic is ready for any questions and for any authoritative expertise of findings
    and will be glad to collaboration with you in favour of global ME/CFS-Community.

    Attachments will be transferred by request.

    Awaiting your feedback and your opinion/review,
    sincerely yours,
    Dr.Oleg Markov, Communications, Markov Clinic, Kyiv, Ukraine.
    Tel. + WhatsApp/Telegram/Viber: +38050 4800268.
    Email: markovos@ukr.net

    Like

Leave a comment